Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study

G. Bolis; G. Bortolozzi; G. Carinelli; M. D'Incalci; F. Gramellini; L. Morasca; C. Mangioni

doi:10.1007/BF00254034

Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study

G. Bolis, G. Bortolozzi, G. Carinelli, M. D'Incalci, F. Gramellini, L. Morasca, C. Mangioni

Research output: Contribution to journal › Article › peer-review

Abstract

After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m² IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.

Original language	English
Pages (from-to)	129-132
Number of pages	4
Journal	Cancer Chemotherapy and Pharmacology
Volume	4
Issue number	2
DOIs	https://doi.org/10.1007/BF00254034
Publication status	Published - 1980

ASJC Scopus subject areas

Cancer Research
Oncology
Pharmacology

Access to Document

10.1007/BF00254034

Cite this

@article{4fa27f7221334044a4a634d7b5a958a8,

title = "Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study",

abstract = "After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.",

author = "G. Bolis and G. Bortolozzi and G. Carinelli and M. D'Incalci and F. Gramellini and L. Morasca and C. Mangioni",

year = "1980",

doi = "10.1007/BF00254034",

language = "English",

volume = "4",

pages = "129--132",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study

AU - Bolis, G.

AU - Bortolozzi, G.

AU - Carinelli, G.

AU - D'Incalci, M.

AU - Gramellini, F.

AU - Morasca, L.

AU - Mangioni, C.

PY - 1980

Y1 - 1980

N2 - After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.

AB - After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.

UR - http://www.scopus.com/inward/record.url?scp=0018826878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018826878&partnerID=8YFLogxK

U2 - 10.1007/BF00254034

DO - 10.1007/BF00254034

M3 - Article

C2 - 7389058

AN - SCOPUS:0018826878

SN - 0344-5704

VL - 4

SP - 129

EP - 132

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2

ER -

Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this